Full-Time

Senior Director – Brand Lead

Marketing

Posted on 10/3/2025

SpringWorks Therapeutics

SpringWorks Therapeutics

201-500 employees

Clinical-stage precision medicines for cancer

Compensation Overview

$200k - $275k/yr

+ Bonus

Boston, MA, USA

Hybrid

This role will be required to work onsite 2 days a week (Tuesday and Wednesday), or more depending on business needs.

Category
Growth & Marketing (1)
Required Skills
Market Research
Financial analysis
Marketing
Data Analysis
Requirements
  • Bachelor's degree (business or related disciplines)
  • MBA preferred
  • 12+ years of pharmaceutical and/or biotechnology commercial experience
  • 5+ years people leadership experience
  • S. Oncology / rare disease experience preferred, including an understanding of the landscape, community and academic oncology dynamics, GPOs, Payer landscape, Specialty Pharmacy stakeholders
  • Prior experience managing outside agencies (creative & media), design firms, and internal teams to execute brand and strategic marketing direction.
  • Proficient in digital marketing and media tactics directed towards HCPs and patients
  • Successful track record in understanding the U.S. regulatory environment and navigating the medical, regulatory, legal review process
  • Proven project and vendor management skills including budget management, planning, prioritization, objective setting, and logistics execution
  • Excellent communication skills with an ability to efficiently and productively communicate both orally and in writing; track record of effective and influential presentations to external and internal stakeholders
  • Proven ability to lead and collaborate with cross-functional teams
  • Strong analytical, problem solving, and strategic thinking skills
  • Demonstrated ability and eagerness to work in a fast-paced environment, striving for excellence in everything you do, alongside a team that is driven by improving the lives of patients
  • Microsoft Office
  • Veeva PromoMats
  • Brand planning
  • Launch and tactical planning
  • Results-oriented, exhibits leadership skills, and ability to influence without authority
  • Clear and inspiring communicator able to engage, influence and navigate cross-functional stakeholders
  • Track record of high-energy, impactful presentations
  • High ethical standards and personal integrity
  • Team player and strong track record of collaboration, particularly across Marketing and Sales teams
  • Model SpringWorks Leadership Principles to drive a collaborative function that embraces innovation and drives superior employee experience through growth management.
  • Embody the SpringWorks Values to act with empathy and humility to drive a culture that takes ownership and accountability for their individual and teams’ performance.
  • Strong interpersonal communication skills to collaborate with colleagues, stakeholders, and vendors effectively and clearly in a remote hybrid work environment.
  • Ability to travel 20-30% including overnight stay driven by business need.
Responsibilities
  • Build, retain, develop, and motivate direct reports, including regular performance feedback and annual reviews
  • Develop a deep understanding of disease state, market dynamics, unmet needs, and brand/competitive data to lead the development and evolution of market shaping and brand building initiatives; Provide thought leadership for market and therapeutic area understanding across all the levels of organization
  • Own brand positioning, branding, campaign, and core messaging across all audiences
  • Lead cross-functional team to successfully develop and execute an annual integrated product plan, including direct alignment to forecast achievement, robust budgets, prioritization of appropriate tactics, and a strong KPI measurement plan with key stakeholders that drives differentiated and compelling value to market segments
  • Develop and execute HCP and patient tactical plans through high-quality, high impact/engagement, innovative promotional and educational initiatives including but not limited to core promotional materials, print and digital sales force tools, promotional and/or educational programming, media planning and other NPP approaches
  • Work with internal and external partners to define success metrics and analyze performance of marketing programs on an ongoing basis, ensuring plans are optimized as needed to improve impact, adjust strategy and tactics accordingly, and develop recommendations for future plans
  • Align with Regional Marketing on the KTL engagement and peer-to-peer education strategy; Ensure appropriate channel mix and content strategy
  • Partner with digital agency of record to develop strategy, execution and measurement for all digital promotion and media, including omnichannel engagement. Lead the creation / updates and delivery of core media assets and .com websites using a data/insights driven approach
  • Collaborate with Market Research, Sales, Regional Marketing and Medical Affairs to develop HCP and patient insights that are actionable; Ensure awareness and education of key internal stakeholders
  • Oversee the planning and execution of GOMEKLI commercial tactics for all congresses, ensuring alignment with overarching strategy
  • Develop and manage strategy, planning, and execution for advisory boards, integrating insights to optimize marketing plans and associated execution
  • Effectively manage the GOMEKLI marketing budget and collaborate with cross-functional partners to optimize spend and maximize the value of investments
  • Effectively contribute to short and long-term brand forecasting
  • Work with Marketing Operations to ensure effective management of GOMEKLI resources in the fulfillment portal
  • Partner with training and sales leadership to optimize the development and utilization of personal resources and ensure appropriate rollout to field teams; Deliver Field Force training and communications as needed
  • Lead team in liaising with training to develop and present brand strategic onboarding deck at all training classes
  • Collaborate cross-functionally with internal teams including Global Marketing, Global Strategic Insights, Sales Operations, Sales, Regional Marketing, Finance, Medical Affairs, and Market Access to advance GOMEKLI
  • Collaborate with broader rare tumor marketing team to ensure strategic alignment and execution across the SpringWorks portfolio
  • Oversee and support promotional material through legal, medical, and regulatory review processes, interpreting scientific data to develop compelling promotional messages
  • Manage agency partner relationships, maintaining a focus on marketing excellence and flawless, on-time execution of key tactics and deliverables
  • Develop and align on KTL quarterly key insights questions with Regional Marketing team
  • Develop and maintain strong relations with key thought leaders
  • Lead development of leadership updates, dept trainings and POA/NSM slide deck development and general brand direction; Lead development of monthly US reporting
  • Conduct regular field rides
  • Ability to independently and proactively identify strategic opportunities, build plans and execute against them
  • Attend and/or participate at conventions, conferences, and tradeshows, preparing engaging displays and collateral as needed, and providing post-event reports and analysis
  • Other duties as assigned
Desired Qualifications
  • S. Oncology / rare disease experience preferred, including an understanding of the landscape, community and academic oncology dynamics, GPOs, Payer landscape, Specialty Pharmacy stakeholders
SpringWorks Therapeutics

SpringWorks Therapeutics

View

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that develops precision medicines for patients with rare diseases and cancer. Its approach is to tailor therapies based on the genetic and molecular profile of a disease, aiming to improve treatment effectiveness and safety for underserved patient groups. The company advances drug candidates through clinical trials (such as Phase 1b and 2) and pursues partnerships with other pharmaceutical companies to acquire, develop, and commercialize therapies. Unlike broader, non-targeted programs, SpringWorks focuses on niche patient populations defined by genetic profiles and collaborates on development and commercialization, broadening access to targeted treatments. The company’s goal is to bring targeted therapies to market that address unmet medical needs in oncology and rare diseases, improving outcomes for patients with specific genetic conditions.

Company Size

201-500

Company Stage

IPO

Headquarters

New York City, New York

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Merck KGaA acquired SpringWorks for $3.9B on July 1, 2025.
  • Acquisition adds immediate revenue from Ogsiveo and Gomekli.
  • CHMP positive opinion for mirdametinib expands EU access.

What critics are saying

  • Merck KGaA drops two SpringWorks pipeline assets post-acquisition.
  • European Commission rejects mirdametinib approval due to pediatric data.
  • Pimicotinib outperforms Ogsiveo in desmoid tumor trials.

What makes SpringWorks Therapeutics unique

  • Ogsiveo is first FDA-approved therapy for desmoid tumors.
  • Gomekli is first approved therapy for NF1-PN in adults and children.
  • Precision medicines target rare cancers via genetic profiling.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Vacation

Paid Sick Leave

Professional Development Budget

Flexible Work Hours

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

5%

2 year growth

5%
AllSci
Mar 17th, 2026
R1 Therapeutics launches with oversubscribed USD 77.5m Series A.

R1 Therapeutics launches with oversubscribed USD 77.5m Series A. March 17, 2026 R1 Therapeutics, a clinical-stage biopharmaceutical company headquartered in Redwood City, California, has launched with an oversubscribed Series A financing totaling USD 77.5 million. The company is focused on developing therapies for chronic kidney disease, the lead program targeting hyperphosphatemia in dialysis patients. R1 acquired exclusive global rights outside of Greater China to that program - AP306, a pan phosphate transporter inhibitor - via a license deal with China-based Alebund Pharmaceuticals announced alongside the Series A. The round was co-led by Abingworth, F-Prime, and DaVita Venture Group, part of DaVita Inc. (NYSE: DVA), with participation from Curie.Bio, SymBiosis, and US Renal Care. The company said proceeds will fund a global development program for AP306, including a Phase IIb study planned to begin later this year. This is R1 Therapeutics' first disclosed funding round, coinciding with the company's formal launch. AP306, previously known as EOS789, was originally discovered by Chugai Pharmaceutical Co. and subsequently licensed to Alebund Pharmaceuticals, which conducted a Phase IIa study in hemodialysis patients in China. Results from that trial, published in Kidney International Reports, showed statistically significant reductions in serum phosphate with a tolerable safety profile. AP306 is described as the only clinical-stage agent that blocks active phosphate transport via three GI-tract transporters - NaPi-2b, PiT-1, and PiT-2 - distinguishing it from phosphate binders, which inhibit passive transport and have been the standard of care for six decades. More than 40% of US dialysis patients fail to reach phosphate targets with existing therapies, which carry high pill burden and GI tolerability issues, the company said. R1 is led by co-founder, president, and CEO Krishna Polu, M.D., a nephrologist with more than 20 years of biopharmaceutical experience. Co-founder L. Mary Smith, Ph.D., who previously served as chief development officer at SpringWorks Therapeutics, joins as chief operating officer. Your email address will not be published. Required fields are marked *

PharmiWeb.com
May 27th, 2025
Springworks Therapeutics Receives Positive Chmp Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With Nf1-Pn

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN. – If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN –. – Decision from European Commission expected in the third quarter of 2025 –

Merck Group
May 5th, 2025
agreement-to-acquire-springworks

Merck KGaA, Darmstadt, Germany, and SpringWorks Therapeutics, have entered into a definitive agreement for us to acquire SpringWorks.

MedCity News
Apr 28th, 2025
Merck KGaA's Rare Tumor Strategy Takes Shape With $3.9B SpringWorks Acquisition

When SpringWorks went public in 2019, the biotech priced its shares at $18 each.

IT Juzi
Apr 28th, 2025
Merck Acquires SpringWorks for $3.9B

German Merck Group has announced a $3.9 billion acquisition agreement with U.S. biopharmaceutical company SpringWorks Therapeutics. This acquisition aims to enhance Merck's cancer drug business. SpringWorks Therapeutics, a biopharmaceutical developer, has obtained four potential new drugs in clinical stages from Pfizer.

INACTIVE